emerge glp-1 Journeys Ease your GLP GLP-1 Drug Pipeline 2026 |

Long-Term Weight Loss & Maintenance with Semaglutide in Obesity (2022 Review of STEP Trials) consolidates findings across multiple STEP trials (1, 3, 4, 8), showing 14.917.4% mean weight loss over 68 weeks, improved cardiometabolic markers, and better quality-of-life outcomes

Glucagon-like peptide-1 receptor agonists during pregnancy and lactation

There's prevention I'm a healthy weight, I'm just starting to see those pounds creep on a little bit

But outreach is still needed to fully inform both patients as well as providers about the program, says Anders Gilberg, senior vice president of government affairs for the Medical Group Management Association

Animals that lack the GLP-1R do not show evidence of liraglutide in the ARC suggesting that peripherally administered liraglutide requires the GLP-1R to enter into the CNS (Secher et al., 2014)